Influenza A/B Inhibitor

We are engaged in an exclusive license and collaboration agreement with Merck Sharp & Dohme Corp. (“Merck”) to discover and develop certain proprietary influenza A/B antiviral agents.  This class of influenza antivirals targets influenza polymerase complex (PB1:PB2:PA) for the treatment of influenza A and B infections. 

Under the terms of the agreement, Merck will fund all research and development for the program, including clinical development, and will be responsible for worldwide commercialization of any products derived from the collaboration. Cocrystal was paid a $4 million license fee and is eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156 million, plus undisclosed royalties on product sales.